Disseminated lymphoblastic lymphoma in children and adolescents: Results of the COG A5971 trial: A report from the Children's Oncology Group

Amanda M. Termuhlen, Lynette M Smith, Sherrie L. Perkins, Mark Lones, Jonathan L. Finlay, Howard Weinstein, Thomas G. Gross, Minnie Abromowitch

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The Children's Oncology Group's A5971 trial examined central nervous system (CNS) prophylaxis and early intensification in paediatric patients diagnosed with CNS-negative Stage III and IV lymphoblastic lymphoma. Using a 2 × 2 factorial design, the study randomized patients to Children's Cancer Group (CCG) modified Berlin-Frankfurt-Muenster (BFM) acute lymphoblastic leukaemia (ALL) regimen with intensified intrathecal (IT) methotrexate (MTX) (Arm A1) or an adapted non-Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT-MTX in maintenance (Arm B1). Each cohort was randomized ± intensification (cyclophosphamide/anthracycline) (Arms A2/B2). For the 254 randomized patients, there was no difference in 5-year event-free survival (EFS) for the four arms: Arm A1, 80% [95% confidence interval (CI) 67-89%] and Arm A2, 81% (95% CI 69-89%); Arm B1, 80% (95% CI 68-88%) and Arm B2, 84% (95% CI 72-91%). The cumulative incidence of CNS relapse was 1·2%. Age <10 years and institutional imaging response at 2 weeks was associated with improved outcomes (P < 0·001 and P = 0·014 for overall survival). CNS positive patients (n = 12) did poorly [5-year EFS of 63% (95% CI 29-85%)]. For CNS-negative patients, there was no difference in outcome based on CNS prophylaxis (IT-MTX versus HD-MTX) or with intensification.

Original languageEnglish (US)
Pages (from-to)792-801
Number of pages10
JournalBritish Journal of Haematology
Volume162
Issue number6
DOIs
StatePublished - Sep 2013

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate
Central Nervous System
Confidence Intervals
Berlin
varespladib methyl
Disease-Free Survival
Maintenance
Anthracyclines
Non-Hodgkin's Lymphoma
Cyclophosphamide
Pediatrics
Recurrence
Survival
Incidence
Neoplasms

Keywords

  • Lymphoblastic lymphoma
  • Non-Hodgkin lymphoma
  • Paediatric

ASJC Scopus subject areas

  • Hematology

Cite this

Disseminated lymphoblastic lymphoma in children and adolescents : Results of the COG A5971 trial: A report from the Children's Oncology Group. / Termuhlen, Amanda M.; Smith, Lynette M; Perkins, Sherrie L.; Lones, Mark; Finlay, Jonathan L.; Weinstein, Howard; Gross, Thomas G.; Abromowitch, Minnie.

In: British Journal of Haematology, Vol. 162, No. 6, 09.2013, p. 792-801.

Research output: Contribution to journalArticle

Termuhlen, Amanda M. ; Smith, Lynette M ; Perkins, Sherrie L. ; Lones, Mark ; Finlay, Jonathan L. ; Weinstein, Howard ; Gross, Thomas G. ; Abromowitch, Minnie. / Disseminated lymphoblastic lymphoma in children and adolescents : Results of the COG A5971 trial: A report from the Children's Oncology Group. In: British Journal of Haematology. 2013 ; Vol. 162, No. 6. pp. 792-801.
@article{4cae26775aff4ea9bc629a42b6f26205,
title = "Disseminated lymphoblastic lymphoma in children and adolescents: Results of the COG A5971 trial: A report from the Children's Oncology Group",
abstract = "The Children's Oncology Group's A5971 trial examined central nervous system (CNS) prophylaxis and early intensification in paediatric patients diagnosed with CNS-negative Stage III and IV lymphoblastic lymphoma. Using a 2 × 2 factorial design, the study randomized patients to Children's Cancer Group (CCG) modified Berlin-Frankfurt-Muenster (BFM) acute lymphoblastic leukaemia (ALL) regimen with intensified intrathecal (IT) methotrexate (MTX) (Arm A1) or an adapted non-Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT-MTX in maintenance (Arm B1). Each cohort was randomized ± intensification (cyclophosphamide/anthracycline) (Arms A2/B2). For the 254 randomized patients, there was no difference in 5-year event-free survival (EFS) for the four arms: Arm A1, 80{\%} [95{\%} confidence interval (CI) 67-89{\%}] and Arm A2, 81{\%} (95{\%} CI 69-89{\%}); Arm B1, 80{\%} (95{\%} CI 68-88{\%}) and Arm B2, 84{\%} (95{\%} CI 72-91{\%}). The cumulative incidence of CNS relapse was 1·2{\%}. Age <10 years and institutional imaging response at 2 weeks was associated with improved outcomes (P < 0·001 and P = 0·014 for overall survival). CNS positive patients (n = 12) did poorly [5-year EFS of 63{\%} (95{\%} CI 29-85{\%})]. For CNS-negative patients, there was no difference in outcome based on CNS prophylaxis (IT-MTX versus HD-MTX) or with intensification.",
keywords = "Lymphoblastic lymphoma, Non-Hodgkin lymphoma, Paediatric",
author = "Termuhlen, {Amanda M.} and Smith, {Lynette M} and Perkins, {Sherrie L.} and Mark Lones and Finlay, {Jonathan L.} and Howard Weinstein and Gross, {Thomas G.} and Minnie Abromowitch",
year = "2013",
month = "9",
doi = "10.1111/bjh.12460",
language = "English (US)",
volume = "162",
pages = "792--801",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Disseminated lymphoblastic lymphoma in children and adolescents

T2 - Results of the COG A5971 trial: A report from the Children's Oncology Group

AU - Termuhlen, Amanda M.

AU - Smith, Lynette M

AU - Perkins, Sherrie L.

AU - Lones, Mark

AU - Finlay, Jonathan L.

AU - Weinstein, Howard

AU - Gross, Thomas G.

AU - Abromowitch, Minnie

PY - 2013/9

Y1 - 2013/9

N2 - The Children's Oncology Group's A5971 trial examined central nervous system (CNS) prophylaxis and early intensification in paediatric patients diagnosed with CNS-negative Stage III and IV lymphoblastic lymphoma. Using a 2 × 2 factorial design, the study randomized patients to Children's Cancer Group (CCG) modified Berlin-Frankfurt-Muenster (BFM) acute lymphoblastic leukaemia (ALL) regimen with intensified intrathecal (IT) methotrexate (MTX) (Arm A1) or an adapted non-Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT-MTX in maintenance (Arm B1). Each cohort was randomized ± intensification (cyclophosphamide/anthracycline) (Arms A2/B2). For the 254 randomized patients, there was no difference in 5-year event-free survival (EFS) for the four arms: Arm A1, 80% [95% confidence interval (CI) 67-89%] and Arm A2, 81% (95% CI 69-89%); Arm B1, 80% (95% CI 68-88%) and Arm B2, 84% (95% CI 72-91%). The cumulative incidence of CNS relapse was 1·2%. Age <10 years and institutional imaging response at 2 weeks was associated with improved outcomes (P < 0·001 and P = 0·014 for overall survival). CNS positive patients (n = 12) did poorly [5-year EFS of 63% (95% CI 29-85%)]. For CNS-negative patients, there was no difference in outcome based on CNS prophylaxis (IT-MTX versus HD-MTX) or with intensification.

AB - The Children's Oncology Group's A5971 trial examined central nervous system (CNS) prophylaxis and early intensification in paediatric patients diagnosed with CNS-negative Stage III and IV lymphoblastic lymphoma. Using a 2 × 2 factorial design, the study randomized patients to Children's Cancer Group (CCG) modified Berlin-Frankfurt-Muenster (BFM) acute lymphoblastic leukaemia (ALL) regimen with intensified intrathecal (IT) methotrexate (MTX) (Arm A1) or an adapted non-Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT-MTX in maintenance (Arm B1). Each cohort was randomized ± intensification (cyclophosphamide/anthracycline) (Arms A2/B2). For the 254 randomized patients, there was no difference in 5-year event-free survival (EFS) for the four arms: Arm A1, 80% [95% confidence interval (CI) 67-89%] and Arm A2, 81% (95% CI 69-89%); Arm B1, 80% (95% CI 68-88%) and Arm B2, 84% (95% CI 72-91%). The cumulative incidence of CNS relapse was 1·2%. Age <10 years and institutional imaging response at 2 weeks was associated with improved outcomes (P < 0·001 and P = 0·014 for overall survival). CNS positive patients (n = 12) did poorly [5-year EFS of 63% (95% CI 29-85%)]. For CNS-negative patients, there was no difference in outcome based on CNS prophylaxis (IT-MTX versus HD-MTX) or with intensification.

KW - Lymphoblastic lymphoma

KW - Non-Hodgkin lymphoma

KW - Paediatric

UR - http://www.scopus.com/inward/record.url?scp=84883279055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883279055&partnerID=8YFLogxK

U2 - 10.1111/bjh.12460

DO - 10.1111/bjh.12460

M3 - Article

C2 - 23889312

AN - SCOPUS:84883279055

VL - 162

SP - 792

EP - 801

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -